



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

RECEIVED
MAR 19 2003
TECH CENTER 1600/2003
3/2003

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
1662/53003

Application Number
10/026,573

Filing Date
December 20, 2001

Examiner
Rachel M. BENNETT

Art Unit
1615

Invention Title
COMPOSITIONS AND DOSAGE FORMS FOR GASTRIC
DELIVERY OF ANTINEOPLASTIC AGENTS AND
METHODS OF TREATMENT THAT USE THEM TO
INHIBIT CANCER CELL PROLIFERATION

Inventor(s)
Moshe FLESHNER-BARAK et al.

Address to:
Commissioner for Patents
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on

Date: 3/10/03

Signature: Bernadette D. Souza


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. A copy of each patent, publication or other information listed on the modified PTO Form No. 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge deposit account number 11-0600 for such fees. A duplicate copy of this Communication is enclosed for charging purposes.

Dated: March 7, 2003

By:

Paul Johnson
Paul Johnson (Reg. No. 35,559)

KENYON & KENYON
1500 K Street, N.W., Suite 700
Washington, DC 20005-1257
(202) 220-4200 (telephone)
(202) 220-4201 (facsimile)



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2800
MAR 19 2003

RECEIVED

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
1662/53003

Application Number
10/026,573

Filing Date
December 20, 2001

Examiner
Rachel M. BENNETT

Art Unit
1615

Invention Title
**COMPOSITIONS AND DOSAGE FORMS FOR GASTRIC
DELIVERY OF ANTINEOPLASTIC AGENTS AND
METHODS OF TREATMENT THAT USE THEM TO
INHIBIT CANCER CELL PROLIFERATION**

Inventor(s)
Moshe FLESHNER-BARAK et al.

Address to:
Commissioner for Patents
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on

Date: 3/10/03

Signature: Bernadette DiSenna

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. A copy of each patent, publication or other information listed on the modified PTO Form No. 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge deposit account number 11-0600 for such fees. A duplicate copy of this Communication is enclosed for charging purposes.

Dated: March 7, 2003

By:

Paul Johnson
Paul Johnson (Reg. No. 35,559)

KENYON & KENYON
1500 K Street, N.W., Suite 700
Washington, DC 20005-1257
(202) 220-4200 (telephone)
(202) 220-4201 (facsimile)